title: Cardio-vascular safety of acetyl cholinesterase inhibitors in patients suffering from Alzheimer's disease; factors that predict poor tolerability.
authors.forename: Daniel
authors.initials: D
authors.lastname: Kinnair
authors.forename: Chip
authors.initials: C
authors.lastname: Machili
authors.forename: Richard
authors.initials: R
authors.lastname: Prettyman
authors.forename: Erik
authors.initials: E
authors.lastname: Van Diepen
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000077265:Donepezil; D005702:Galantamine / Q000009:adverse effects; D006801:Humans; D007189:Indans / Q000009:adverse effects; D015999:Multivariate Analysis; D048448:Phenylcarbamates / Q000009:adverse effects; D010880:Piperidines / Q000009:adverse effects; D012189:Retrospective Studies; D000068836:Rivastigmine
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D048448:Phenylcarbamates; D010880:Piperidines; D005702:Galantamine; D000077265:Donepezil; D000068836:Rivastigmine